Journal of critical care
-
Journal of critical care · Dec 2022
Randomized Controlled TrialMuscle size, strength, and physical function in response to augmented calorie delivery: A TARGET sub-study.
Augmented calories may attenuate muscle loss experienced in critical illness. This exploratory sub-study assessed the effect of augmented calorie delivery on muscle mass, strength, and function. ⋯ Augmented calorie delivery may not attenuate muscle loss or recovery of strength or function 6-months post-ICU, but this requires exploration in a larger trial.
-
Journal of critical care · Dec 2022
Factors associated with occurrence and severity of acute kidney injury in patients with Sepsis - A retrospective database study.
Sepsis remains the most common cause of acute kidney injury (AKI) and is associated with a high mortality. This study aims to identify laboratory, clinical and demographic factors that are associated with the different stages of AKI in sepsis. ⋯ Presepsis creatinine levels, mechanical ventilation, comorbidities, and positive blood cultures were associated with AKI.
-
Journal of critical care · Dec 2022
The impact of obesity on the outcome of severe SARS-CoV-2 ARDS in a high volume ECMO centre: ECMO and corticosteroids support the obesity paradox.
The aim was to verify the impact of obesity on the long-term outcome of patients with severe SARS-CoV-2 ARDS. ⋯ The high incidence of obesity was not associated with worse short and long-term outcomes. ECMO in obese patients together with the use of steroids in the later stage of ARDS may improve survival.
-
Journal of critical care · Dec 2022
Physicians' attitudes and perceptions of neuromuscular blocker infusions in ARDS.
The perceptions and practices of ICU physicians regarding initiating neuromuscular blocker infusions (NMBI) in acute respiratory distress syndrome (ARDS) may not be evidence-based amidst the surge of severe ARDS during the SARS-CoV-2 pandemic and new practice guidelines. We identified ICU physicians' perspectives and practices regarding NMBI use in adults with moderate-severe ARDS. ⋯ Most intensivists agreed NMBI in ARDS should be reserved until after a deep sedation trial. Stopping criteria remain poorly defined. Unique considerations exist regarding the role of paralysis in COVID-19+ ARDS.